Journal Article

Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial

Hachulla, Eric, Mariampillai, Kuberaka, Hij, Adrian, Guiguet, Marguerite, Devilliers, Herve, Drouot, Laurent, Herson, Serge, Jouen, Fabienne, Jacquot, Serge, Grenier, Philippe, Musset, Lucile, Rigolet, Aude, Marie, Isabelle, Boyer, Olivier, Allenbach, Yves, Benveniste, Olivier

2015

Overview

Anti-synthetase syndrome (anti-SS) is frequently associated with myositis and interstitial lung disease (ILD). We evaluated prospectively, in a multicenter, open-label, phase II study, the efficacy of rituximab on muscle and lung outcomes. Patients were enrolled if they were refractory to conventional treatments (prednisone and at least 2 immunosuppressants). They received 1 g of rituximab at D0, D15, and M6. The primary endpoint was muscular improvement based on manual muscular testing (MMT10, Kendall score in 10 muscles) at M12. Secondary endpoints were normalization of creatine kinase (CK) level, ILD improvement based on forced vital capacity and/or diffuse capacity for carbon monoxide, and number and/or doses of associated immunosuppressants. Twelve patients were enrolled, and 10 completed the study. Only 2 patients presented an improvement of at least 4 points on at least two muscle groups (primary end-point). Overall, seven patients had an increase of at least 4 points on MMT10. CK level decreased from 399 IU/L (range, 48-11,718) to 74.5 IU/L (range, 40-47,857). Corticosteroid doses decreased from 52.5 mg/d (range, 10-70) to 9 mg/d (range, 7-65) and six patients had a decrease in the burden of their associated immunosuppressants. At baseline, all 10 patients presented with ILD. At M12, improvement of ILD was observed in 5 out of the 10 patients, stabilization in 4, and worsening in 1. This pilot study of rituximab treatment in patients with refractory anti-SS provided data on evolution of muscular and pulmonary parameters. Rituximab should now be evaluated in a larger, controlled study for this homogenous group of patients. Clinicaltrials.gov NCT00774462.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adult / Antibodies / Autoantibodies / Autoantibodies - immunology / Carbon monoxide / Clinical trials / Corticosteroids / Creatine / Creatine kinase / Creatine Kinase - blood / Female / Human health and pathology / Humans / Immunoglobulins / Immunologic Factors - therapeutic use / Immunosuppressive agents / Immunotherapy / Inflammation / Inflammatory diseases / Life Sciences / Lung diseases / Male / Middle Aged / Monoclonal antibodies / Muscles / Musculoskeletal diseases / Myositis / Myositis - drug therapy / Neutrophils / Patients / Prednisone / Rheumatoid arthritis / Rheumatology / Rhumatology and musculoskeletal system / Rituximab / Rituximab - therapeutic use / Studies / Treatment Outcome / Viral infections / Vital Capacity / Young Adult